Ex-Novartis Exec Rahman To Steer Clinical Sciences At Glenmark

Dr. Mahboob Rahman, a former Novartis therapeutic area head for immunology in global clinical development, joins Glenmark at a key juncture as the Indian firm advances several key R&D assets including in immuno-oncology.  “Portfolio prioritization” and bringing in the right talent rank high on Rahman’s immediate agenda, while a “fast-paced” environment appears to be among the key draws for his move.

Science
GLENMARK ROPES IN BIG PHARMA EXEC TO HEAD CLINICAL SCIENCES

Moving from Big Pharma to the clinical development space in a relatively smaller Indian firm isn’t generally the norm given the potentially huge differences in scale and scope of operations, besides the budgets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

More from Scrip